G1 Therapeutics Inc’s recently made public that its Chief Financial Officer Umstead John W. V unloaded Company’s shares for reported $19752.0 on Mar 18 ’24. In the deal valued at $3.02 per share,6,547 shares were sold. As a result of this transaction, Umstead John W. V now holds 123,896 shares worth roughly $0.59 million.
Then, Malik Rajesh sold 28,600 shares, generating $132,143 in total proceeds. Upon selling the shares at $4.62, the Chief Medical Officer now owns 169,938 shares.
Before that, MURDOCK TERRY L sold 721 shares. G1 Therapeutics Inc shares valued at $2,121 were divested by the Chief Operating Officer at a price of $2.94 per share. As a result of the transaction, MURDOCK TERRY L now holds 103,638 shares, worth roughly $0.49 million.
JP Morgan upgraded its G1 Therapeutics Inc [GTHX] rating to a Neutral from a an Underweight in a research note published on January 30, 2023; the price target was increased to $10 from $7. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in early January has reiterated a ‘”a Buy”‘ rating for it. JP Morgan also remained covering GTHX and has decreased its forecast on November 04, 2021 with a “an Underweight” recommendation from previously “Neutral” rating.
Price Performance Review of GTHX
On Monday, G1 Therapeutics Inc [NASDAQ:GTHX] saw its stock fall -0.21% to $4.77. Over the last five days, the stock has gained 4.84%. G1 Therapeutics Inc shares have risen nearly 56.39% since the year began. Nevertheless, the stocks have risen 91.57% over the past one year. While a 52-week high of $5.00 was reached on 02/08/24, a 52-week low of $1.08 was recorded on 02/13/24. SMA at 50 days reached $3.66, while 200 days put it at $2.49. A total of 1.06 million shares were traded, compared to the trading of 0.85 million shares in the previous session.
Levels Of Support And Resistance For GTHX Stock
The 24-hour chart illustrates a support level at 4.45, which if violated will result in even more drops to 4.13. On the upside, there is a resistance level at 4.97. A further resistance level may holdings at 5.16. The Relative Strength Index (RSI) on the 14-day chart is 68.47, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.44, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 4.39%. Stochastics %K at 92.99% indicates the stock is a selling.
How much short interest is there in G1 Therapeutics Inc?
A steep rise in short interest was recorded in G1 Therapeutics Inc stocks on Mar 15, 2024, dropping by -0.64 million shares to a total of 2.69 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 3.33 million shares. There was a decline of -23.79%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 5.21% of the overall stock float, the days-to-cover ratio (short ratio) fell to 2.21.
